Boundless Bio

BOLD

Biotechnology · Healthcare

Price

$2.48

-0.01 (-0.40%)

Market Cap

$55.7M

Exchange

NASDAQ Global Select

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Boundless Bio is a small biotechnology company focused on developing cancer treatments. It targets a specific genetic abnormality called extrachromosomal DNA, or ecDNA, which helps some tumors grow aggressively and resist standard therapies. The company is working on drugs designed to attack this mechanism, with the goal of treating patients whose cancers have not responded well to existing options.

Boundless Bio earns no revenue yet, as its drug candidates are still in early clinical trials. It operates primarily in the United States and funds its research through cash raised from investors. With a market cap of roughly $100 million and deeply negative returns on capital, the company faces the typical risks of a pre-revenue biotech: it must continue raising money to survive while proving its drugs are safe and effective. The key risk is clinical failure — if its lead programs do not show strong results in trials, the company could struggle to attract further funding.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+15.5% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$45M/ year

↓ Declining (-19% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

23.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~19 months

$93M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.5% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 22.2M (2021) → 22.4M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-11.0%

Weak — -11.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.52

Conservative — low debt load (0.52)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial